Biomarker ID | 60 |
PMID | 15655565 |
Year | 2005 |
Biomarker | BCL-2 |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Upregulated in PCa Patients: PSA >10 ng/ml |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include:-Interleukin-7 signaling pathway,BAD phosphorylation regulation,Apoptosis intrinsic pathway,RXR/VDR pathway,Corticotropin releasing hormone pathway |
Experiment | PSA ≤10 ng/ml Vs PSA >10 ng/ml |
Type of Biomarker | Prognostic |
Cohort | 126 patients were chosen for the study and divided into 2 groups- Early Stage (clinically localized disease) (n=72) and Late Stage Metastatic AI disease (n=54) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.01 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | COX-2, bcl-2 and MVD (Microvessel Density) for neoangiogenesis were chosen for biomarker evaluation |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | BCL-2 |